Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-921 pembrolizumab plus docetaxel versus placebo plus docetaxel in metastatic castration-resistant prostate cancer after next-generation hormonal therapy
jRCT2080224754Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Keytruda + docetaxel + prednisone with Placebo + docetaxel + prednisone (2 arms). Primary endpoints: Radiographic progression-free survival and Overall survival. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on jRCT2080224754.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224754.